A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.
Aelis Farma, a France-based drug developer spun out of Inserm, has listed on Euronext Paris following a €25m ($28.1m) initial public offering. Aelis Farma’s shareholders include Inserm’s tech transfer office, Inserm Transfert Initiative, which had helped the spinout raise a total of $14m prior to the flotation.
Dive Technologies, a US-based subsea robotics developer that is collaborating with Virginia Tech, has agreed to an acquisition by defence technology producer Anduril Industries for an undisclosed amount. Dive Technologies had obtained $4m of financing from VTC Ventures, Tanis Venture Management, Mill Town Capital, Cavalier Angels and Charlottesville Angel Network in December 2020.
HeartFlow, a US-based developer of non-invasive technology to generate a three-dimensional model of a patient’s heart, has cancelled its plans to go public through a reverse merger with Longview Acquisition Corporation II that it had announced in July 2021. The Stanford University spinout cited unfavourable market conditions for the decision. HeartFlow has raised some $543m in funding to date, according to press reports and regulatory filings, from investors including Blue Venture Fund, a vehicle for members of insurance association Blue Cross Blue Shield.
